Media Release - For immediate release

22nd December 2008

YoungHeart Manawatu has successfully signed a naming rights sponsor for the 2008/09 New Zealand Football Championship (NZFC) season by naming New Zealand Pharmaceuticals (NZP), as the Principle Naming Rights Sponsor.

NZP General Manager, Andy Lewis announced the signing today and believes it is a great move for his business.

Mr Lewis says, “We feel responsible to support sport and recreation in our community and feel YoungHeart Manawatu are a great example of a regional franchise which can foot it with the best in the country.”

 “It’s also important to support initiatives that further develop our great region. We want this city to be a vibrant place for our employees to live.”

 NZP’s affinity to football doesn’t stop there with a number of excited staff already putting their hands up to be involved on game day.

 “We’ll have a great presence at the home games and with free gate entry, I am sure there will be many more that will come along” Mr. Lewis says.

YoungHeart Sponsorship and Marketing Manager, Troy Thurston is delighted with the founding of the relationship and believes it is the beginning of great things.

 “Creating a relationship like this is valuable for the team and the community. It not only provides some real value for the current season but also some stability for the future of the franchise, and we can’t wait to work with NZP,” Mr. Thurston says.

Manawatu’s NZFC footballing franchise will now be known as NZP YoungHeart Manawatu.

Next home game: NZP YoungHeart Manawatu versus Canterbury United at Memorial Park on Saturday the 10th January. Kick off at 1pm and FREE gate entry.

New Zealand Pharmaceuticals and Commonwealth Biotechnologies Enter into Glycotherapeutic Drug Discovery and Development Strategic Alliance.

April 7, 2008

New Zealand Pharmaceuticals and Commonwealth Biotechnologies Enter into Glycotherapeutic Drug Discovery and Development Strategic Alliance.

Palmerston North, New Zealand. -  New Zealand Pharmaceuticals Ltd (“NZP”)  is pleased to announce that it has entered into a global Strategic Alliance Agreement with Commonwealth Biotechnologies, Inc. (CBI) (NASDAQ Capital Market: CBTE) to provide a suite of small molecule chemistry products for the drug discovery, development and manufacturing markets. The Alliance will focus on providing glycotherapeutic products and services for research through to process scale-up and commercialization by way of an exclusive referral and co-marketing agreement.  CBI, through its wholly owned subsidiary Exelgen Ltd, will provide customers with research grade products and services and NZP will supply customers with identified lead candidates for pre-clinical applications through to cGMP products for clinical and therapeutic applications.

The CBI/NZP co-branded drug development services will be jointly marketed and promoted to both company’s customer bases and to the broader pharmaceutical and biotechnology market.  Dr Paul D’Sylva of CBI said that “this Alliance follows in the footsteps of the very successful alliance agreement that CBI, through its wholly owned subsidiary Mimotopes Pty Ltd, has with Genzyme Pharmaceuticals in the field of peptide chemistry. Following the acquisition of medicinal and synthetic chemistry contract research provider Exelgen in June 2007, the partnership with NZP will provide a parallel suite of specialty products and services to the rapidly growing and evolving glycotherapeutics area. CBI ultimately aims to provide clients with a seamless link between drug discovery and the clinic for all its major service areas, thus capturing more value down the supply chain and proving the market with a truly vertically integrated product offering.”

Dr Richard Garland, Managing Director of NZP said “the Alliance is about enhancing the product offering of both companies by offering customers a full package of drug discovery, development and production services. This reduces time to market for our customers and ensures that all stages of their discovery, development and manufacturing programs are supported by the highest quality service providers.”

About New Zealand Pharmaceutical Ltd

Since 1971, New Zealand Pharmaceuticals (NZP) has been leading the way for the biotechnology industry development in New Zealand. 

The company manufactures and exports pharmaceutical intermediates and active pharmaceutical ingredients supported by EDQMs, DMFs and Medicines Licences to the world's leading pharmaceuticals and biotechnology companies. NZP expanded its focus recently to include synthetic small molecule and carbohydrate compounds. It also produces a range of dietary supplements and diagnostics products.  For more information, visit NZP on the web at www.nzp.co.nz and for more information on synthesis, visit www.nzpsynthesis.com.

About Commonwealth Biotechnologies, Inc.

The CBI group of companies offers cutting-edge research and development products and services to the global life sciences industry. CBI now operates four distinct business units: (1) CBI Services, a discovery phase contract research organization; (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes Pty, Ltd, Melbourne, Australia, a peptide and discovery chemistry business; and (4) Exelgen, Ltd, Bude, UK, a medicinal and synthetic discovery chemistry business. Collectively, CBI companies employ over 100 staff in world-class laboratories. For more information, visit CBI on the web at www.cbi-biotech.com.

NZP will attend BIO (June 17 - 20) in San Diego as a part of the New Zealand delegation. The New Zealand Pavilion will be located at Booth #4434.

Come and meet us at CPhI.  NZP will be attending the following CPhI shows in 2008:

SHOW	CITY	DATES	STATUS	BOOTH
	Tokyo, Japan	9-11 April 2008	Exhibitor	J-30
	Shanghai, China	24-26 June 2008	Visitor
	Rio de Janeiro, Brazil	19-21 August 2008	Visitor
	Frankfurt, Germany	30 Sep - 2 Oct 2008	Exhibitor
	Mumbai, India	28-30 Nov 2008	Exhibitor

Dr Richard Garland, NZP’ Managing Director, has received Government recognition in the New Year honours list.  He has been appointed as an Officer of the Order of New Zealand Merit for his services to chemistry and pharmaceuticals. "I am fortunate to have had a great team at NZP which has enabled us to make a useful contribution to the  NZ economy over the years." Dr Garland
	Dr Richard Garland, NZP Managing Director